Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases.
COVID-19
Diabetes
Organ damage
SGLT2 inhibitors
Journal
International journal of clinical pharmacy
ISSN: 2210-7711
Titre abrégé: Int J Clin Pharm
Pays: Netherlands
ID NLM: 101554912
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
12
01
2021
accepted:
22
02
2021
pubmed:
23
3
2021
medline:
2
7
2021
entrez:
22
3
2021
Statut:
ppublish
Résumé
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new class of glucose-lowering agents which have changed the landscape of diabetes therapy, due to their remarkable cardiorenal protective properties. The attack of severe acute respiratory syndrome coronavirus 2 on the heart and kidneys shares similarities with diabetes; therefore, the notion that SGLT2i might have a role in the future management of Coronavirus Disease 2019 (COVID-19) is based on a solid pathophysiological hypothesis. SGLT2i have been proved to decrease the expression of proinflammatory cytokines, ameliorate oxidative stress and reduce sympathetic activity, thus resulting in downregulation of both systemic and adipose tissue inflammation. On the other hand, they have been linked to an increased risk of euglycemic diabetic ketoacidosis. Therefore, the efficacy and safety of SGLT2i in COVID-19 are still debatable and remain to be clarified by ongoing randomized trials, to assess whether the benefits of treatment with these drugs outweigh the potential risks.
Identifiants
pubmed: 33751323
doi: 10.1007/s11096-021-01256-9
pii: 10.1007/s11096-021-01256-9
pmc: PMC7942520
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
764-767Références
Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–46.
doi: 10.1056/NEJMoa2024816
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24.
doi: 10.1056/NEJMoa2022190
Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020. https://doi.org/10.1002/dmrr.3319 .
doi: 10.1002/dmrr.3319
pubmed: 33275827
pmcid: 7228407
Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001;88:E14-22.
doi: 10.1161/01.RES.88.2.e14
Koufakis T, Mustafa OG, Ajjan RA, Garcia-Moll X, Zebekakis P, Dimitriadis G, et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: is the risk worth taking? J Clin Pharm Ther. 2020;45:883–91.
doi: 10.1111/jcpt.13107
Packer M. Do sodium-glucose co-transporter 2 inhibitors prevent heart failure with a preserved ejectionfraction by counterbalancing the effects of leptin? A novel hypothesis. Diabetes Obes Metab. 2018;20:1361–6.
doi: 10.1111/dom.13229
Das L, Dutta P. SGLT2 inhibition and COVID-19: The road not taken. Eur J Clin Invest. 2020;50:e13339.
doi: 10.1111/eci.13339
Tajbakhsh A, Gheibi Hayat SM, Akbari A, Inabadi M, Savardashtaki A, et al. COVID-19 and cardiac injury: clinical manifestations, biomarkers, mechanisms, diagnosis, treatment, and follow up. Expert Rev Anti Infect Ther. 2020. https://doi.org/10.1080/14787210.2020.1822737 .
doi: 10.1080/14787210.2020.1822737
pubmed: 32921216
Dherange P, Lang J, Qian P, Oberfeld B, Sauer WH, Koplan B, et al. Arrhythmias and COVID-19: a review. JACC Clin Electrophysiol. 2020;6:1193–204.
doi: 10.1016/j.jacep.2020.08.002
Chen HY, Huang JY, Siao WZ, Jong GP. The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study. Cardiovasc Diabetol. 2020;19:73.
doi: 10.1186/s12933-020-01048-x
Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 Diabetes Mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141:1227–34.
doi: 10.1161/CIRCULATIONAHA.119.044183
Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med. 2020;38:1722–6.
doi: 10.1016/j.ajem.2020.05.073
Cure E, Cure MC. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabet Metab Synd. 2020;14:405–6.
doi: 10.1016/j.dsx.2020.04.024
Oliveira CB, Lima CAD, Vajgel G, Campos Coelho AV, Sandrin-Garcia P. High burden of acute kidney injury in COVID-19 pandemic: systematic review and meta-analysis. J Clin Pathol. 2020. https://doi.org/10.1136/jclinpath-2020-207023 .
doi: 10.1136/jclinpath-2020-207023
pubmed: 33234697
Menon R, Otto EA, Sealfon R, Nair V, Wong AK, Theesfeld CL, et al. SARS-CoV-2 receptor networks in diabetic and COVID-19 associated kidney disease. Kidney Int. 2020;98:1502–18.
doi: 10.1016/j.kint.2020.09.015
Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, et al. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019;62:1154–66.
doi: 10.1007/s00125-019-4859-4
Dalan R, Ang LW, Tan WYT, Fong SW, Tay WC, Chan YH, et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother. 2020. https://doi.org/10.1093/ehjcvp/pvaa098 .
doi: 10.1093/ehjcvp/pvaa098
Armeni E, Aziz U, Qamar S, Nasir S, Nethaji C, Negus R, et al. Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. Lancet Diabetes Endocrinol. 2020;8:660–3.
doi: 10.1016/S2213-8587(20)30221-7
Chamorro-Pareja N, Parthasarathy S, Annam J, Hoffman J, Coyle C, Kishore P. Letter to the editor: unexpected high mortality in COVID-19 and diabetic ketoacidosis. Metabolism. 2020;110:154301.
doi: 10.1016/j.metabol.2020.154301
Batista DV, Vieira CAFA, Costa TA, Lima EG. COVID-19-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes on SGLT2 inhibitor: a case report. Diabetol Int. 2020. https://doi.org/10.1007/s13340-020-00473-3 .
doi: 10.1007/s13340-020-00473-3
pubmed: 33133998
pmcid: 7592186